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Abdominal aortic aneurysm (AAA) is characterized by transmural infiltration of myeloid cells at the 
vascular injury site. Previously, we reported preventive effects of Notch deficiency on the development 
of AAA by reduction of infiltrating myeloid cells. In this study, we examined if Notch inhibition 
attenuates the progression of pre-established AAA and potential implications. pharmacological 
Notch inhibitor (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl ester; DAPT) was 
administered subcutaneously three times a week starting at day 28 of angiotensin II (AngII) infusion. 
Progressive increase in pulse wave velocity (PWV), maximal intra-luminal diameter (MILD) and maximal 
external aortic diameter (MEAD) were observed at day 56 of the AngII. DAPT prevented such increase 
in MILD, PWV and MEAD (P < 0.01). Histologically, the aortae of DAPT-treated Apoe−/− mice had 
significant reduction in inflammatory response and elastin fragmentation. Naked collagen microfibrils 
and weaker banded structure observed in the aortae of Apoe−/− mice in response to AngII, were 
substantially diminished by DAPT. A significant decrease in the proteolytic activity in the aneurysmal 
tissues and vascular smooth muscle cells (vSMCs) was observed with DAPT (P < 0.01). In human and 
mouse AAA tissues, increased immunoreactivity of activated Notch signaling correlated strongly 
with CD38 expression (R2 = 0.61). Collectively, we propose inhibition of Notch signaling as a potential 
therapeutic target for AAA progression.
Abdominal aortic aneurysm (AAA) is a localized dilation of the abdominal aorta exceeding the normal diameter 
(~20 mm) by 1.5 times (≥30 mm)1. In the United States, AAA accounts for more than 9,000 deaths per year2. 
Pharmacological approaches to limit progression of small AAA (30–50 mm) using anti-inflammatory drugs have 
not been successful3,4. Surgical interventions for the large AAAs (>50 mm) are associated with a significant finan-
cial burden and do not provide long-term survival advantages for the small AAAs (≥30–50 mm)5–7. These limited 
options for treatment of AAA highlight the need for innovative research to halt the progression of the disease.
Clinical and experimental research has identified infiltration of immune cells contributing to aneurysm initi-
ation8,9. Progression of AAA is accompanied by differentiation of vSMC into a synthetic phenotype in the medial 
layer, their apoptotic cell death and perpetual expansion of adventitial layer10,11. These pathways have empha-
sized the contribution of aortic vSMCs to aortic wall stiffness via phenotypic changes and extracellular matrix 
(ECM) dysregulation12,13. Previously, we showed that Notch inhibition prevents the development of early AAA 
in AngII-mouse model by macrophage-dependent mechanisms14. Studies by us and others have also established 
direct effects of Notch1 signaling on vSMCs in vascular diseases15–17. Notch signaling has been implicated in 
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vSMCs phenotypic malformations both as a positive and a negative regulator18,19. However, the effects of inhibi-
tion of Notch signaling on pre-established AAA as a therapeutic target have never been explored.
Hypothesizing that inhibition of Notch signaling will induce regression/stabilization of pre-established 
aneurysm in an experimental model of AngII-induced AAA, we inhibited Notch signaling at day 28, with or 
without prolonged AngII infusion. The study was intended to mimic the clinical setting in which a therapeutic 
drug may be administered in the absence or presence of underlying secondary causes. We demonstrate that 
Notch inhibition stabilizes pre-established AAA and increases the factors of stability in an experimental model of 
AngII-induced AAA via a CD38 signaling dependent mechanism.
Results
Notch inhibition reverses aortic stiffness and promotes factors of AAA stability. To examine the 
therapeutic potential of the Notch inhibitor (N-[N-(3,5-difluorophenacetyl)-L-alanyl]-(S)-phenylglycine t-butyl 
ester; DAPT) on the progression and stability of pre-established AAA, we used an AngII-induced mouse model of 
AAA in our studies. Transabdominal ultrasound imaging showed a significant increase in the MILD (1.59 ± 0.34 
vs. 0.90 ± 0.03 mm, P < 0.001), PWV (1.50 ± 0.28 vs. 0.93 ± 0.04 m/s, P < 0.001), and a decrease in distensibility 
(74.2 ± 18.8 vs. 103.7 ± 9.99 1/MPa, P < 0.001) and radial strain (24.9 ± 7.89 vs. 53.1 ± 4.2%, P < 0.001) in the 
Apoe−/− mice in response to AngII than controls at day 28 (Supplementary Fig. 2 and data not shown).
With the cessation of AngII, no further increase in MILD was observed at day 56 (1.67 ± 0.40 mm; Fig. 1A,C). 
However, PWV increased progressively and was significantly higher at day 56 (1.94 ± 0.19 m/s) compared to 
day 28 (Fig. 1D). At day 56, MILD in the DAPT-treated mice (1.41 ± 0.39 mm) was not significantly differ-
ent compared to AngII 28d. Interestingly, DAPT prevented further increase in PWV (1.42 ± 0.22 m/s) such 
that it was significantly lower than AngII 28d (P < 0.01; Fig. 1D and Supplementary Fig. 2). Prolonged AngII 
led to increase in MILD (1.87 ± 0.37 mm) and PWV (2.17 ± 0.20 m/s) at day 56 (P < 0.01). Infusion of DAPT 
had modest-to-striking effects on MILD and PWV in the aorta with prolonged AngII treatment. Although a 
marginal increase in MILD (1.53 ± 0.45 mm; Fig. 1C) was observed at day 56, no further progression of PWV 
(1.27 ± 0.27 m/s, Fig. 1D) was observed and it was significantly lower than AngII 56d (P < 0.01). It is important to 
distinguish that at day 28, PWV correlated strongly with MILD (R2 = 0.51, Fig. 1B), whereas at day 56, the corre-
lation between PWV and MILD was relatively weak (R2 = 0.22; Supplementary Fig. 2C). DAPT treatment did not 
affect distensibility or radial strain significantly (Fig. 1E,F).
Consistent with the ultrasound data, the macroscopic examination of aortae at day 56 demonstrated a signifi-
cantly increased MEAD in response to AngII in both the groups (AngII 28d and AngII 56d) compared to controls 
(1.67 ± 0.47 and 2.03 ± 0.38 vs. 0.87 ± 0.07 mm respectively; P < 0.05; Fig. 2A,B). The increase in the MEAD in 
DAPT-treated mice was significantly reduced (1.38 ± 0.55 and 1.41 ± 0.41 mm in AngII 28d + DAPT and AngII 
56d + DAPT respectively) as compared to their counterparts (P < 0.05). It is important to note that at day 56, the 
correlation between PWV and MEAD was not significant (R2 = 0.09; Supplementary Fig. 2D). The correlation 
between MILD and MEAD, however, remained strong in these experimental groups (R2 = 0.88; Supplementary 
Fig. 2E).
At day 56, the AAAs in AngII 28d and AngII 56d were classified as type III in ~60% (11/18) and type II in 
~25% (4/18) of the mice (P < 0.05; Fig. 2C). With DAPT treatment, AAAs were classified as ~35% (6/18) as type 
III and ~55% (10/18) as type II (P < 0.01). Overall mortality and weights were not significantly different among 
these groups from day 28 to 56 of AngII (data not shown). One mouse in each of the prolonged AngII group died 
from acute aortic rupture after 28 days as ascertained through post-mortem examination (Fig. 2C).
At day 28 of the AngII, there was marked fragmentation of elastin and loss of vSMCs within the medial 
layer and a thickened adventitia consisting of inflammatory infiltrate (Supplementary Fig. 3). AAA continued to 
expand and exhibited complex pathology in AngII 28d and AngII 56d (Fig. 2D–F). Significant disruption of the 
elastic lamellar architecture in the medial layer was observed at day 56 in AngII 28d (Fig. 2D,E). Prolonged AngII 
further increased elastin fragmentation in AngII 56d mice (P < 0.001; Fig. 2D,G). DAPT significantly reduced 
elastin fragmentation compared to their counterparts (P < 0.05; Fig. 2G). More importantly, newly synthesized 
elastin was increased in the DAPT-treated groups in the vicinity of elastin breaks (inserts in Fig. 2E). Consistent 
with our previous reports14, robust increase in tropoelastin immunostaining was observed in the abdominal aorta 
of mice treated with DAPT (Fig. 2F,H; P < 0.01). Minimal characteristic features of AAA including aortic remod-
eling were observed with DAPT treatment in these mice. Elastin crosslinking genes were differentially affected 
by AngII (Supplementary Fig. 4). The expression of tropoelastin (Eln1) was significantly decreased in response to 
AngII, whereas the expression of emilin1 and lysyl oxidase (Lox) increased significantly. The expression of latent 
transforming growth factor beta binding protein 1 (Ltbp1) remained unaffected with AngII. Notch inhibition 
increased the gene expression of Eln1 and Ltbp1, but the expression of Lox increased marginally. It is interest-
ing that with prolonged infusion of AngII, these protective effects of Notch inhibition on elastin crosslinking 
genes were diminished (Supplementary Fig. 4). No significant differences in the serum lipid levels were detected 
with DAPT treatment in these experimental mice at day 56 (Supplementary Fig. 5). Expression of Notch1, its 
downstream target HeyL and upstream ligand Jagged1 were significantly increased in the AngII treated groups 
(Supplementary Fig. 6). In accordance within our previous studies, DAPT reduced Notch1 and HeyL expression 
by more than 50% whereas expression of Jagged1 was marginally reduced14. As reported earlier14, gastrointestinal 
toxicity, including goblet cell metaplasia, and dilatation of intestinal crypts/glands was observed in the treated 
mice by Periodic Acid–Schiff (PAS) staining (data not shown). Interestingly, marginal proliferation of goblet 
cells and mucosal epithelial necrosis was also observed in the Apoe−/− mice treated with AngII (data not shown). 
Overall, these findings suggested that Notch inhibition at late stage of the disease ameliorate the progressive 
growth of AAA and also lessened the aortic stiffness of the aorta.
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notch inhibition minimizes collagen and ecM degradation. Aortic stiffness in AAA is primarily 
determined by the loss of collagen and ECM-related changes in aortic wall architecture20. Medial collagen depo-
sition was observed in the elastin breaks-adjacent segments with AngII infusion and DAPT treatment minimized 
such deposition (yellow arrows; Fig. 3A).
We previously reported defects in the organization and ultra-architecture of collagen within AAA, which 
correlate with aortic stiffness21. At day 56, abundant naked and abnormal collagen microfibrils with weakened 
banded structure and undulating longitudinal profile were observed in AngII 28d mice in the region close to 
elastin disruption (red arrows; middle panel, Fig. 3B). Abnormal endothelial disruption, vacuolization and thick-
ening were also observed in these groups (upper panel; Fig. 3B). Prolonged treatment with AngII (56d) exhibited 
severe collagen damage and substantial aortic disruption. Interestingly, DAPT reduced the amount of abnormal 
collagen microfibrils and preserved the elastic lamina along with large areas of dense compacted collagen and 
differing degrees of preserved banded structure. The aortic tissues from these DAPT treated mice exhibited less 
endothelial disruption and vacuolization than their counterparts (Fig. 3B). No visible abnormal collagen fibrils 
were observed in the control mice without AngII.
D-periodic spacing of type I collagen is the key metric of collagen fibril morphology22. Increase in d-spacing 
was observed at day 56 in AngII 28d and AngII 56d mice (57.8 ± 2.86 and 62.0 ± 3.03 nm respectively; Fig. 3C) 
compared to controls (45.2 ± 1.47 nm; P < 0.01). Notch inhibition significantly lowered the d-spacing (52.6 ± 2.50 
and 55.5 ± 3.29 nm), compared to respective counterparts (P < 0.01). Together, these data suggest that the 
Figure 1. Stabilization of AAA progression by Notch inhibition. (A) Representative transabdominal ultrasound 
images showing the maximal intraluminal diameter (MILD) at day 0, 28, 42 and 56 of indicated experimental 
groups. DAPT was started at day 28. Dotted yellow lines outline the lumen. (B) Graph showing Pearson’s 
correlation between PWV and MILD from mice receiving AngII and DAPT for 28 days. (C) Quantification of 
MILD in indicated groups as measured by ultrasound (n = 16–18). (D–F) PWV, distensibility and radial strain 
at various days of AngII and DAPT treatments as measured by Vevo Vasc analysis (n = 6–8). Student’s t test 
followed by Bonferroni post hoc analysis was used for the individual time points in (C–F) and ANOVA followed 
by Tukey’s multiple comparison analysis . *P < 0.05; **P < 0.01; ***P < 0.001; ns = non-significant.
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treatment with DAPT results in partial restoration of elastin and collagen fibers, thereby resulting in aneurysm 
stability.
notch inhibition reduces proteolytic activity of aorta and vSMcs. Proteolytic activity and loss 
of vSMCs contribute to the progression of AAA by weakening and stiffening of the medial layer23. A signifi-
cant increase in the matrix metalloproteinase (Mmp) activity in the abdominal aortae was observed in AngII 
28d and AngII 56d mice (P < 0.001, Fig. 4A,C) in the regions of elastin breaks. Conversely, DAPT significantly 
decreased the proteolytic activity, suggesting protective effects against aneurysm propagation in the aortic wall of 
Apoe−/− mice (Fig. 4A,C). The crosstalk between vascular and inflammatory cells contributes to the progression 
of AAA. To investigate the interaction between vSMCs and macrophages with regard to proteolytic activity, we 
Figure 2. Notch inhibition restores the structural integrity of aorta. (A) Representative images showing 
changes in maximal external aortic diameter (MEAD) of suprarenal aorta in the various experimental groups. 
(B) Quantification of MEAD of suprarenal aorta (mm) as measured by microscopy (n = 16–18). (C) Aneurysm 
severity (type I to IV) scored using a classification system and analyzed by Fisher exact test. (D) Representative 
histological images showing H&E staining in the experimental groups at 56 days of DAPT treatment. (E,F) 
Representative immunohistochemistry (IHC) images of aorta showing elastin and tropoelastin staining in the 
indicated groups. (G,H) Quantification of elastin fragmentation scores and tropoelastin expression (n = 6). 
Tukey multiple comparisons test was used for data analysis in (G-H). *P < 0.05; ***P < 0.001; ns = non-
significant. Scale bar = 1mm in A and 50 µm in (D–F).
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employed the transwell coculture system. MMP2 activity in these HaSMCs was significantly decreased by direct 
inhibition of Notch or through Notch-deficient macrophages as determined by gelatin zymography (Fig. 4B,D,E). 
Interestingly, MMP9 activity was also observed in the HaSMCs cocultured with macrophages and DAPT abol-
ished it (Fig. 4B and Supplementary Fig. 7). Overall, Notch inhibition in the macrophages seems to be sufficient 
to influence the proteolytic activity of vSMCs through some unknown factors.
Notch inhibition reduces inflammatory cytokines and synthetic phenotype of vSMCs. To iden-
tify factors which could influence proteolytic activity, cDNA from abdominal aorta was analyzed with a panel of 
inflammatory cytokines and markers of vSMC phenotype. Gene expression of Ctgf, Mmp2, and Mmp9 signifi-
cantly increased in the abdominal aorta of AngII 28d and AngII 56d mice at day 56 compared to control (Fig. 5F–
H). DAPT significantly reduced the expression of Ctgf and Mmp9 in both experimental groups. Immunostaining 
for smMHC revealed that DAPT treatment resulted in partial restoration of vSMCs in the medial layer (P < 0.01; 
Fig. 5J). Immunostaining of Ctgf on the other hand was significantly reduced with DAPT treatment (P < 0.01; 
Fig. 5K) at day 56.
Figure 3. Notch Inhibition minimizes collagen and ECM degradation. (A) Representative trichrome images of 
aorta showing collagen contents in the indicated groups. (B) Representative transmission electron microscopy 
(TEM) images comparing collagen bundles/fibers and D-spacing of collagen molecules. (C) Quantification of 
D-spacing in experimental groups as determined by TEM (n = 4). Tukey multiple comparisons test was used 
for data analysis in C. *P < 0.05; **P < 0.01; ***P < 0.001. Scale bar = 50 µm in A and 5 µm in top, 0.2 µm in the 
middle and 50 nm in the lower panel of B.
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Gene expression of Il6, Il12, and Cd38 increased significantly in AngII 28d and AngII 56d mice at day 56 com-
pared to controls, whereas, expression of iNos was not significantly changed (Fig. 5A–D). With Notch inhibition, 
significant decrease in the expression of Il6 and Cd38, was observed at day 56 as compared to their respective 
controls. Expression of Il12 was decreased with Notch inhibition only in AngII 56d + DAPT. Expression of iNos, 
and M2 genes including cMyc, Egr2, Mgl2 and Tgfβ2 was not significantly altered with AngII or DAPT at day 56 
(data not shown).
CD38 pathway has been recently recognized as an intermediate towards activation of antigens in AAA24 and 
it plays a functional role in inflammatory diseases and vSMCs apoptosis25–28. At day 56, Notch inhibition led to 
significantly lower abundance of Cd38 positive cells in the adventitial region of aorta (Fig. 5I,L). Flow cytometry 
of abdominal aorta at day 56 showed a high percentage of Cd38 positive F4/80+/Ly6Chigh and F4/80+/Ly6Clow 
macrophages in AngII 28d and AngII 56d mice (Fig. 5O). Inhibition of Notch significantly lowered Cd38+ mac-
rophages in the abdominal vascular wall in both the treatment groups, particularly in the Ly6Clow cell population 
and Ly6G+ neutrophils (Supplementary Fig. 8). DAPT had no effect on the expression of Cd38+ macrophages 
from bone marrow, spleen or peripheral blood mononuclear cells from these experimental groups (data not 
shown). Overall, these data indicate that Notch inhibition-induced protective effects on AAA progression may be 
associated with inhibition of CD38 signaling.
Activation of Notch and CD38 signaling in human AAA. Next, we examined the crosstalk of Notch 
activation with Cd38 signaling in human AAA. Increased immunostaining of NICD was observed in the 
inflammation-predominant area of AAA compared to abdominal aortic samples from age-matched non-AAA 
controls (Fig. 6A,B; red). Increased CD38 immunostaining was also observed in these inflammatory regions of 
tissues from AAA subjects (Fig. 6B; green). Quantification of the co-localization analysis demonstrated a signifi-
cant increase in the double-positive cells (DPCs) for NICD and CD38 (Fig. 6C, 66.2% in AAA as compared to 4% 
in controls (R2 = 0.61; white arrows in Fig. 6B). Overall, these data demonstrated increased CD38 positive cells in 
the human AAA, and their linear correlation with Notch signaling.
In summary, our data demonstrate protective roles of Notch inhibition on aortic stiffness and proteolytic 
activity in a mouse model of AAA at the mid-to-late stage of the disease. Mechanistically, Notch deficiency medi-
ated its protective effects on AAA progression by inactivating the CD38 dependent pathway.
Figure 4. Notch Inhibition decreases proteolytic activity of the aorta and vSMCs. (A) Representative in situ 
zymography (ISZ) images showing the proteolytic activity in the aorta. (B) MMP2 and MMP9 activity in the 
HaSMCs cultured alone or with macrophages in the presence and absence of DAPT as determined by gelatin 
zymography. (C) Quantification of proteolytic activity by ISZ (n = 4). (D,E) Quantification of pro- and active 
MMP2 from three independent experiments using ImageJ software. Tukey multiple comparisons test was 
used for data analysis in (C,D,F). Paired two-tailed Student’s t test was used in C-E. **P < 0.01; ***P < 0.001; 
ns = non-significant. Scale bar = 50 µm in A.
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Figure 5. Notch inhibition reduces inflammatory cytokines and synthetic phenotype of vSMCs in the aorta. 
(A–D) mRNA expression of inflammatory cytokines (Cd38, Il6, Il12 and iNos) in the aorta of experimental 
mice (n = 4). (E–H) mRNA expression of genes related to vSMC phenotype (smMHC, Ctgf, Mmp2 and Mmp9) 
in the aorta of experimental mice (n = 4). (I–K) Representative IHC images showing immunoreactivity of Cd38 
(yellow dotted lines in the adventitial region), smMHC and Ctgf in the suprarenal aorta. (L–N) Quantification 
of Cd38, smMHC and Ctgf contents (n = 6). (O) Flow cytometry of the abdominal aorta for Cd38 in various 
subpopulations including CD11b+Ly6C+ macrophages (left panel), CD11b+Ly6Clow macrophages (middle 
panel) and CD11b+Ly6G+ neutrophils at day 56 of the experimental mice (n = 4). ANOVA followed by Tukey’s 
multiple comparison analysis was performed for (A–H,L–O). *P < 0.05; **P < 0.01; ***P < 0.001; Scale 
bar = 50 µm.
8Scientific RepoRtS |         (2019) 9:13458  | https://doi.org/10.1038/s41598-019-49682-0
www.nature.com/scientificreportswww.nature.com/scientificreports/
Discussion
The present study was carried out to investigate the therapeutic potential of Notch inhibition on the stability and 
regression of pre-established AAA using AngII-induced Apoe−/− mouse model. DAPT, a potent pharmacological 
Notch inhibitor was administered at day 28 (late-stage) of AngII infusion and continued for the next 28 days in 
the absence or presence of prolonged AngII. We provide evidence that Notch inhibition decreases the proteolytic 
activity and reduces the aortic stiffness without significantly affecting the diameter of the aneurysm. Furthermore, 
we observed strong correlation of Notch with CD38 signaling, a pro-inflammatory intermediate in human AAA 
and experimental models. Accordingly, Notch inhibition downregulated CD38 signaling in AAAs and in mac-
rophages. In summary, our studies provide experimental evidence that treatment with Notch inhibitor has the 
potential to reverse the aortic stiffness and attenuate the progression of the disease and is a potentially viable 
therapeutic strategy for the AAA, as depicted in our proposed model (Fig. 7).
In addition to the diameter of the AAA, other parameters may provide important information to assess 
the stability of AAAs. Aortic stiffening is an early change generating aortic wall stress that triggers aneurysmal 
growth, and remodeling29. Measurement of PWV is a reliable and reproducible approach to determine aortic 
Figure 6. NICD and CD38 expression is upregulated in the aorta of AAA human subjects. (A) Representative 
H&E images of abdominal aortic sections from non-AAA and AAA human subjects (4X and 40X). (B) 
Representative double immunofluorescence images showing NICD and CD38 immunostaining in the aorta 
of non-AAA and AAA human subjects (4X and 40X). (C) Pearson’s correlation graphs showing the coefficient 
values of NICD/CD38 expression. Scale bar = 50 µm.
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stiffness and seems to be independent of arterial pressure30,31. Our novel findings that Notch inhibitor provides 
stability to the established AAAs by improving the aortic stiffness as primary outcome, have potential therapeutic 
implications.
AAA progression is attributed to aortic wall degeneration, including elastin fragmentation and immature col-
lagen deposition and proteolytic activity of vSMCs32. During the AAA remodeling and ECM repair, the degraded 
collagen is replaced with stiffer and monomeric collagen fibrils. It is important to note that increased synthesis 
of ECM proteins including collagens by vSMCs serves an important compensatory role during the early stages 
of aneurysm development. However, ultrastructural defects in the medial elastic fibers and collagen microfibrils 
observed in the AngII-treated mice may increase susceptibility to rupture33. Accordingly, infusion of DAPT in 
our studies resulted in partial restoration of elastin and collagen fibers, increased amount of tropoelastin and 
minimal thickening of the adventitia suggesting a potential mechanism by which Notch inhibition improves 
aortic stiffness.
We and others have shown that Notch1-dependent phenotypic modulation of vSMCs may also be an impor-
tant factor to influence vascular pathology15,34. Under physiological conditions, vSMCs exist in a contractile 
state and express a unique repertoire of proteins including α-SMA, SM22α and smMHC that serve as contrac-
tile markers35,36. Production of profibrogenic cytokines by synthetic vSMCs including CTGF and osteopontin 
contribute to increased proteolytic activity and defective synthesis of immature ECM components37. We and 
others have demonstrated that preserving or restoring the contractile phenotype of vSMCs attenuates AAA pro-
gression10,15,16. A strong correlation of aortic stiffness with Mmps is also reported in mouse models of AAA29. 
Proteolytic activity of the vSMC-rich medial layer is greatly modulated at the cellular level by cross-talk among 
the neighboring cells in the aorta38. Macrophages secrete a number of cytokines that mediate complex cell–cell 
interactions, and maintain and amplify the inflammation cascade in aortic tissue. From the present studies, we 
infer that infiltration of macrophages into the aorta results in the establishment of a cross-talk among these two 
types of cells whereby each cell instructs the other to produce increased amounts of MMPs.
CD38, an ADP ribosyl cyclase, is a 45 kDa type II transmembrane protein expressed on the surface of various 
cells including macrophages and lymphocytes and is involved in the regulation of NF-κB signaling39,40. NFκB 
signaling also regulates the transcription of genes coding for extracellular proteases and vSMC phenotype and 
could therefore play a role in the aortic remodeling. Based on these observations in human and experimental 
AAA, we speculate that Notch-mediated CD38 activation might be involved in one of the distinctive and specific 
aspects of the inflammatory response related to AAA progression. Further studies are required to address the role 
of CD38 crosstalk with Notch pathway using antibody neutralization or gene deletion strategies in the context of 
AAA pathogenesis.
Our findings carry a high translational impact as numerous commercially available pharmacological Notch 
inhibitors including DAPT are already undergoing clinical trials for other conditions. These Notch inhibitors belong 
to a class of gamma secretase inhibitors (GSIs), and are at different phases of clinical trials in cancer, Alzheimer dis-
ease, graft-versus-host diseases and other T cell-mediated human disorders, their roles in AAA are however, largely 
unknown41,42. GSIs are aspartyl proteases responsible for the terminal cleavage of the β-amyloid precursor protein 
(APP) and more than 90 substrates for γ-secretase inhibitors have been identified43. Thus, we cannot rule out the 
non-targeted effects of DAPT in the context of AAA and future studies are warranted to specifically target Notch1 
for mechanistic insights. Blockade of the Notch pathway by DAPT also suppresses neointimal formation and vas-
culitis in mice44,45. Our findings and the recent literature provide new perspectives for targeting the Notch pathway 
for the potential treatment of effectively limiting AAA progression or the risk of rupture in humans. The presence 
of apparent adverse effects of DAPT on gastrointestinal toxicity are consistent with our previous studies and liter-
ature using the GSIs14,41. Overcoming these adverse effects should also be a goal of future research. In conclusion, 
Notch inhibition reduces the aortic stiffness, which is a measure of AAA progression. Our studies identified a novel 
mechanism for Notch-induced NFκB activation and interactions between macrophages and vSMCs in the context 
of AAA. Applications of Notch inhibitors in larger animal models of AAA will give a new perspective for novel target 
discovery and the development of new strategies to prevent or delay AAA formation.
Figure 7. Schematic interpretation of study findings.
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Methods
Mice, aneurysm model, experimental groups and DAPT treatment. All the animal-related exper-
iments were approved by the Animal Care and Use Committee (ACUC #8799) at the University of Missouri 
(Columbia, MO) and the Institutional Animal Care and Use Committee (IACUC, #AR11-00031) of the Research 
Institute at Nationwide Children’s Hospital. All the animal experiments conformed to the NIH guidelines (Guide 
for the Care and Use of Laboratory Animals). Only male mice were studied for the in vivo studies because of low 
incidence of AngII-induced AAA in female mice as described46. The ‘arrive guidelines’ were followed to plan the 
in vivo studies. Comprehensive details of all the materials and methods are provided in the Supplemental data. 
Aneurysmal studies were performed on these mice by infusing AngII following published protocols47,48. Mice 
were anesthetized in a closed chamber with 1–2% isoflurane inhalation in oxygen for 2 to 5 min until immobile. 
Each mouse was then removed and taped on a heated (37 ± 2 °C) procedure board with 1.0–1.5% isoflurane 
administered via nosecone during minor surgery. The study was conducted in 4 groups of mice as explained 
(Supplemental Fig. 1). DAPT (10 mg/kg dissolved in 10% ethanol, 90% corn oil; Sigma-Aldrich) was adminis-
tered in some of the groups as described14. The dose of DAPT for in vivo experiments was used in accordance 
with our previous studies and literature14,48–50. At the end of the study, the mice were euthanized by overdose of 
ketamine (100 mg/kg) and xylazine (20 mg/kg) intraperitoneally according to our previous studies15. Blood was 
drawn and the aortae were perfused with either saline or a fixative depending upon the experiment.
Transabdominal ultrasound imaging, pulse wave velocity (PWV), distensibility and radial strain 
measurements. For ultrasonic imaging (ECHO), mice were restrained for <15 seconds to put into the 
anesthesia chamber, followed by anesthetization with oxygen and vaporized isoflurane (~1–2%). Loss of spinal 
reflexes were confirmed via toe pinching, and the loss of corneal reflex was assessed by gentle touch of the eye 
with a soft tissue paper technique. The animals were placed on a heated (41°C) imaging stage in supine position 
while under anesthesia. The body temperature, heart beat and respiration rates were continuously monitored 
during the imaging procedure. 40 MHz high-frequency array transducer (Vevo MS550D) was used to collect 
B-mode, M-Mode, ECG-based kilohertz Visualization (EKV) mode images as well as Power Doppler measure-
ments by the imaging system (Vevo 2100, VisualSonics)30,48. In vivo aortic stiffness was measured locally in the 
abdominal aorta by PWV technique by analyzing EKV data collected at various days of AngII infusion using Vevo 
Vasc software as described previously30,51. The measurements for all PWV, distensibility and radial strains were 
conducted following the two-man principle who were blinded to the study groups.
AAA classification. AAA complexity was determined by Daugherty’s classification by measurement of the 
aortic diameter and histological features52. Increase in the MEAD by ≥50% was defined as presence of an AAA.
Serum lipid quantification. Animals were fasted for 4–6 h before blood collection by cardiac puncture as 
described previously53. Serum was separated and lipid analysis was performed by Comparative Clinical Pathology 
Services in Columbia, Missouri, USA using commercially available assays.
Histology, immunohistochemistry (IHC) and qRT-PCR. The abdominal aortae from experimental 
mice were fixed overnight in 10% formalin, rinsed with PBS and processed as described previously15. We used 
low magnification images (4X scale bar) in the HE staining to show the overall aortic remodeling and histologic 
structures and high magnification (40X) in the IHC to show specific immunostaining for different antibodies. For 
IHC, the abdominal aortae were stained with antibodies for NICD (1:400 ab8925), CD38 (1:200, AF4947; R & D), 
smooth muscle myosin heavy chain (smMHC, 1:400, ab53219), connective tissue growth factor (CTGF; 1:400, 
ab6992), TUNEL (11684795910; Roche) and tropoelastin (1:200; ab21600) as described15. The intensity of the 
immunostaining was evaluated by obtaining 4–5 images from random areas of interest at 40X from each tissue 
(n = 6–8) and quantified using Fiji version of ImageJ following the software directions54. The specificity of all the 
antibodies was confirmed using appropriate IgG controls in place of primary antibodies at same concentrations 
as described30. Total RNA was extracted from the aortae using the Fibrous RNeasy kit (Qiagen) following the 
manufacturers’ instructions. Quantitative real-time PCR (qRT-PCR) was performed on CFX connect™ real-time 
PCR detection system (Biorad) in triplicate. CT for Rpl13a was used to normalize gene expression30. The primer 
sequences for genes is detailed in Supplementary Tables 1 and 2. Throughout the study we use gene symbols avail-
able from the National Center for Biotechnology Information (NCBI; http://www.ncbi.nlm.nih.gov/).
Human AAA tissue samples and double immunofluorescence (DIF). Full-thickness aortic wall tis-
sue specimens were collected from the infrarenal abdominal aorta from patients undergoing AAA repair oper-
ations (n = 6; white men aged 60–75 years) at the Harper University Hospital in Detroit, Michigan as described 
previously14,55. The human tissues were obtained after informed consent and approved by the institutional review 
board of Wayne State University in Detroit, Michigan as described in previous studies48,55,56. All the methods in 
the present study were carried out in accordance with the approved guidelines. Aortic tissue was analyzed for 
CD38 along with either NFκB or with NICD using DIF. Images were captured using LionHeart fx microscope57. 
Fluorescence intensity was quantified using Gen 5 software (BioTek).
coculture assay. Human aortic SMCs (HaSMCs; CC-2571, P5-7, Lonza) were subjected to Notch inhibi-
tion through either direct treatment with DAPT or co-cultured with peritoneal macrophages which were pre-
treated with DAPT for 48 h. HaSMCs were grown in DMEM medium (10569-010; Gibco) containing 10% FBS, 
1% penicillin-streptomycin, 4 µg/ml rH Insulin (12585-014; Fisher Scientific), 5 ng/ml recombinant human 
EGF (PHG0311L; Invitrogen) and 50 µg/ml ascorbic acid (A4544-25G; Sigma)15. Peritoneal macrophages were 
obtained as described58. Cell suspension was centrifuged at 4 °C at 2000 rpm for 5 min. Peritoneal macrophages 
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were co-cultured with HaSMCs for 48 h in plain DMEM media. Culture media was processed for gelatin zymog-
raphy and cells were processed for qRT-PCR analysis.
Gelatin zymography and In situ zymography (iSZ). Cultured media was concentrated 50-fold using 
Amicon Ultracel- 10 K centrifugal filter (Millipore, UFC801096) and proteins were separated by electrophoresis, 
gels were stained with Coomassie blue stain after renaturation/activation and then destained. Images of the zymo-
gram were quantified using ImageJ software59. Aortic tissues were cut and incubated with substrate solution con-
taining DQ gelatin (D12054; Invitrogen) and ISZ was performed as described60. Negative control sections were 
treated without DQ gelatin. Sections were mounted with Vectashield medium with DAPI (H-1800; Vector Labs). 
Fluorescence intensity in the medial layer of the tissue sections was quantified using Gen 5 software (BioTek).
transmission electron microscopy (teM) for mouse aortic tissue samples. Samples were prepared 
at the Electron Microscopy Core Facility, University of Missouri following a modified version of National Center 
for Microscopy and Imaging Research (NCMIR) methods for 3D EM61. Images were acquired with JEM 1400 
transmission electron microscope (JEOL) at 80 kV on Ultrascan 1000 CCD (Gatan, Inc). Difference in length of 
d-period for collagen fibrils was measured as described previously62.
Single cell preparation for flow cytometric analysis. We isolated the abdominal aortic cells as 
described previously15. Harvested cells were counted per mouse and incubated in saturated doses of anti-mouse 
Fc receptor in 100 μl of ice-cold FACS buffer (1% bovine serum albumin/0.01% NaN3 in PBS) for 15 min. After 
washing, 2 × 106 cells were stained with various combinations of antibodies in ice-cold FACS buffer for 15 min, 
and further collected on a LSR II cytofluorometer (BD Biosciences). Gating strategies are shown in Supplementary 
Fig. 8. Data were analyzed with FlowJo software (Tree Star).
Statistical analysis. Statistical analyses were performed using GraphPad Prism version 7.0 (GraphPad 
Software, Inc., CA). Unpaired two-tailed Student’s t test was used to determine statistical difference between 
two groups for normally distributed continuous variables. For comparison of multiple groups, ANOVA followed 
by Tukey’s multiple comparison analysis or 2-way ANOVA followed by Bonferroni post hoc tests were used. 
Data are presented as median ± interquartile range for the PWV, MILD and MEAD. For rest of the quantitation, 
mean ± SEM was calculated. Pearson’s correlation coefficients were used to calculate correlation analyses. P < 0.05 
was considered statistically significant for all tests. The ultrasound and IHC quantitation was done in blinded 
fashion following the “two-man” principle to ensure scientific precision.
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